Specificity and selectivity profile of EP217609: A new neutralizable dual-action anticoagulant that targets thrombin and factor Xa

Blood

Volumn 119, Issue 10, 2012, Pages 2187-2195

  Olson, Steven T ^a   Swanson, Richard ^a   Petitou, Maurice ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Endotis Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AVIDIN; BLOOD CLOTTING FACTOR 10A; EP 217609; EP 217609 1; EP 307138 1; EP 42675; FIBROLASE; FONDAPARINUX; IDRAPARINUX; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL;

EID: 84858016010     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-381764     Document Type: Article

References (37)

1. Hirsh J. Heparin. N Engl J Med. 1991;324(22): 1565-1574.
2. Björk I, Olson ST. Antithrombin. A bloody important serpin. In: Church FC, Cunningham DD, Ginsburg D, Hoffman M, Stone SR, Tollefsen DM, eds. Chemistry and Biology of Serpins. New York, NY: Plenum Press; 1997:17-33.
3. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 2003; 85(1):83-89. (Pubitemid 36625983)
4. Olson ST, Björk I. Mechanism of action of heparin and heparin-like antithrombotics. Persp Drug Disc Des. 1994;1(3):479-501.
5. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost. 2003;1(7):1471-1478.
6. Shafer JA. Cardiovascular chemotherapy: anticoagulants. Curr Opin Chem Biol. 1998;2(4):458-465. (Pubitemid 128645698)
7. Warkentin TE, Levine MN, Hirsh J, et al. Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
8. van Boeckel CAA, Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem. 1993;32(12):1671-1690.
9. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG34006, a potent and long acting synthetic pentasaccharide. Blood. 1998;91(11):4197-4205. (Pubitemid 28261983)
10. Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267(18):12528-12538.
11. Samama M-M, Gerotziafas GT. Evaluation of the pharamacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res. 2003;109(1):1-11. (Pubitemid 36385042)
12. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90(3): 1522-1536. (Pubitemid 24284473)
13. Petitou M, van Boeckel CAA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew Chem Int Ed Engl. 2004;43(24):3118-3133.
14. de Kort M, Buijsman RC, van Boeckel CAA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Disc Today. 2005;10(11):769-779.
15. Petitou M, Nancy-Portebois V, Dubreucq G, et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost. 2009;102(5):804-810.
16. Buijsman RC, Basten JEM, Van Dinther TG, van der Marel GA, van Boeckel CAA, van Boom JH. Design and synthesis of a novel synthetic NAPAP- pentasaccharide conjugate displaying a dual antithrombotic action. Bioorg Med Chem Lett. 1999;9(14):2013-2018. (Pubitemid 29336392)
17. Vogel GMT, Meuleman DG, Van Dinther TG, Buijsman R, Princen AWM, Smit MJ. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J Thromb Haemost. 2003;1(9): 1945-1954.
18. Neuhart E, Gueret P, Krezel C, Fuseau E, Petitou M. Neutralizable parenteral anticoagulation: EP217609 and its specific antidote, avidin, in healthy subjects. A new paradigm? J Thromb Haemost. 2011;9(suppl 2):106.
19. Shore-Lesserson L, Gravlee GP. Anticoagulation for cardiopulmonary bypass. In: Gravlee GP, Davis RF, Stammers AH, Ungerleider RM, eds. Cardiopulmonary Bypass: Principles and Practice. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008:472-501.
20. Gouault-Heilmann M, Huet Y, Contant G, Payen D, Bloch G, Rapin M. Cardiopulmonary bypass with a low molecular weight heparin fraction. Lancet. 1983;2(8363):1374. (Pubitemid 14245053)
21. Marshall LR, Cannell PK, Herrmann RP. Successful use of the APTT in monitoring of the antifactor Xa activity of the heparinoid organon 10172 in a case of HITS requiring open heart surgery. Thromb Haemost. 1992;67(5):587.
22. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTIONON study. J Thorac Cardiovasc Surg. 2006; 131(3):533-539.
23. Gasparovic H, Nathan NS, Fitzgerald D, Aranki SF. Severe argatroban-induced coagulopathy in a patient with a history of heparin-induced thrombocytopenia. Ann Thorac Surg. 2004;78(6):e89-e91. (Pubitemid 39556317)
24. Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA. A novel antidotecontrolled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther. 2006;14(3):408-415. (Pubitemid 44184966)
25. Olson ST, Swanson R, Raub-Segall E, et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems: comparison with heparin and low-molecular-weight heparin. Thromb Haemost. 2004;92(5):929-939. (Pubitemid 39545514)
26. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-560.
27. Nordenman B, Nyström C, Björk I. The size and shape of human and bovine antithrombin III. Eur J Biochem. 1977;78(1):195-203. (Pubitemid 8164738)
28. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-685.
29. Lewis SD, Lucas BJ, Brady SF, et al. Characterization of the two-step pathway for inhibition of thrombin by α-ketoamide transition state analogs. J Biol Chem. 1998;273(9):4843-4854. (Pubitemid 28108633)
30. Sturzebecher J, Kopetzki E, Bode W, Hopfner K-P. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS Lett. 1997;412(2):295-300. (Pubitemid 27321269)
31. Izaguirre G, Zhang W, Swanson R, Bedsted T, Olson ST. Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin. J Biol Chem. 2003;278(51):51433- 51440. (Pubitemid 38020383)
32. Hjelm R, Schedin-Weiss S. High-affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha/beta-antithrombin is predominantly due to nonionic interactions. Biochemistry. 2007;46(11):3378-3384. (Pubitemid 46449156)
33. Olson ST, Bock PE, Kvassman J, et al. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family: contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem. 1995;270(50):30007-30017.
34. Izaguirre G, Swanson R, Raja SM, Rezaie AR, Olson ST. Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin. J Biol Chem. 2007;282(46):33609-33622. (Pubitemid 350159518)
35. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost. 2008;6(10):1697- 1706.
36. Sturzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikstrom P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J Med Chem. 1997;40(19):3091-3099. (Pubitemid 27391541)
37. Sturzebecher J, Markwardt F, Voight B, Wagner G, Walsmann P. Cyclic amides of N-alpha-arylsulfonylaminoacylated 4-amidinophenylalanine: tight binding inhibitors of thrombin. Thromb Res. 1983;29(6):635-642. (Pubitemid 13080955)